info@p-95.com

proposal request

Clinical Trial Delivery

Comprehensive Clinical Trial Support for Vaccines and Infectious Disease.

Data, Analysis and writing

Our data management, biostatistics, safety management and medical writing teams ensure data integrity and insightful analysis for vaccines and drugs across all stages of development.

Epidemiology and Real-World Evidence (RWE) Solutions

Comprehensive Epidemiology and RWE solutions for Vaccines and Infectious Diseases.

Africa and LMICs

Expanding Clinical and Epidemiological Horizons: Expertise in Africa, LMICs, and Beyond.

VIEW ALL SERVICES

All News

Read Article

Read Article

News

Celebrating P95’s Anniversary: From our Humble Beginnings to a Global Full-Service CRO

By P95

June 10, 2024

As we approach our 13th anniversary on June 16, we pause to celebrate important milestones and extend our deepest gratitude to our staff, partners and clients who have been part of our growth journey! From our humble beginnings to becoming a global full-service CRO focused on vaccines and infectious diseases, each step has been marked by dedication and a commitment to excellence. 

Joining forces with Ampersand Capital Partners in May 2023 and our merger with OnQ Research in October 2023, were pivotal moments allowing us to expand our capabilities and physical presence in over 30 countries. The opening of our new office in North Carolina, USA, in early 2024, further exemplified our commitment to becoming a global force in the healthcare sector. We look forward to continuing our mission of delivering innovative solutions and making a positive impact on global health.

Happy birthday P95!

More about P95’s history

P95

Pioneering Clinical Excellence in Vaccines and Infectious Diseases

Tags:

0 Comments

You May Also Like

P95’s Journey From Epidemiology Consulting to Comprehensive CRO

P95’s Journey From Epidemiology Consulting to Comprehensive CRO

Apr 12 |

In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).

Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.

P95 welcomes John O’Brien as Chief Business Officer

P95 welcomes John O’Brien as Chief Business Officer

Mar 6 |

We are excited to welcome John O’Brien as our new Chief Business Officer! John has a proven track record of driving commercial success and building strategic partnerships, bringing a wealth of experience to our team.